Why NeuBase Therapeutics Popped by 16.5% on Friday

What happened

NeuBase Therapeutics (NASDAQ: NBSE) ended the week on a real sugar high, rising by nearly 17% on Friday. This was due to a glowing note about the biotech from one of its more prominent investors.

So what

The praise came from Greenlight Capital, the hedge fund run by noted investor David Einhorn. On Thursday, Greenlight released the latest quarterly update on its performance.

As is its habit, Greenlight dived into the particulars of several portfolio investments, among which was NeuBase. Greenlight waxed enthusiastic about the company’s PATrOL platform, a cutting-edge technology which modifies the protein function of genes in order to precisely target diseases.

Image source: Getty Images.

“By addressing all of the causal mechanisms underlying rare and common diseases –- including cancer –- PATrOL consolidates the capabilities of highly valued gene silencing, gene editing and gene replacement companies in a single unified platform,” Greenlight wrote in its assessment.

Describing the risk-reward proportion of NeuBase as “asymmetrical,” Greenlight believes PATrOL has the potential to be a game-changing technology that could help fight a wide range of afflictions.

Now what

Greenlight is a true believer in that potential; it originally began loading up on NeuBase stock in the third quarter of 2019, and has since added several times to its holdings.

While the hedge fund manager’s assessment of the company’s prospects is believable, we should bear in mind that NeuBase is still a preclinical-stage biotech with no products on the market, and thus carries a very high degree of risk as an investment.

10 stocks we like better than NeuBase Therapeutics, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and NeuBase Therapeutics, Inc. wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of November 20, 2020

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *